Business Context and Reporting Period
Company: IOVANCE BIOTHERAPEUTICS, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 22, 2025
Event: Entry into a Material Definitive Agreement regarding an equity offering program.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the authorization of a potential capital raise:
- Maximum Offering Size: Up to $350.0 million of common stock.
- Commission Rate: Up to 3.0% of gross sales proceeds payable to the sales agent.
- Trading Symbol: IOVA (Nasdaq Stock Market, LLC).
Material Changes
On August 22, 2025, the Company entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC. This agreement establishes an "at-the-market" (ATM) offering program, allowing the Company to issue and sell shares of its common stock through Jefferies acting as a sales agent. The issuance is subject to a prospectus supplement dated August 22, 2025, filed under a registration statement on Form S-3ASR originally filed on June 16, 2023.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company retains sole discretion over whether to sell shares, the timing of sales, and the number of shares sold. The Company is not obligated to make any sales under the agreement. Sales will be conducted based on instructions from the Company, including price or size limits.
Risks and Contingencies:
- Dilution: The sale of shares under the ATM program will result in dilution to existing shareholders.
- Costs: The Company will incur a commission of up to 3.0% on gross proceeds.
- Legal Obligations: The Company has agreed to indemnify Jefferies against certain liabilities under the Securities Act and the Securities Exchange Act of 1934.
- Termination: The offering will terminate upon the termination of the Agreement in accordance with its terms.
Investor Verification Checklist
- Verify the current share price and market capitalization to assess the potential dilution impact of a $350.0 million offering.
- Review the full text of the Amended and Restated Open Market Sale Agreement (Exhibit 1.1) for specific termination clauses and conditions.
- Monitor future filings to determine if and when the Company elects to sell shares under this program.
- Check the Company's cash position in recent 10-Q or 10-K filings to understand the liquidity necessity driving this ATM authorization.